医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Q4 and FY17 Financial Results

2017年05月12日 PM10:51
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2017 under International Financial Reporting Standards (IFRS).

FY17: Key Highlights

  • Revenues at Rs. 140.8 billion: YoY decline: 9%
  • Gross Profit Margin at 55.6%
  • Research & Development (R&D) spend at Rs. 19.6 billion [13.9% of Revenues]
  • Selling, general & administrative (SG&A) expenses at Rs. 46.4 billion [YoY increase: 1%]
  • EBITDA at Rs. 25.5 billion [18.1% of Revenues]
  • Profit after tax at Rs. 12.0 billion [8.5% of Revenues]

Q4 FY17: Key Highlights

  • Revenues at Rs. 35.5 billion: QoQ decline: 4%; YoY decline: 5%
  • Gross Profit Margin at 51.2%
  • R&D spend at Rs. 4.6 billion [12.9% of Revenues]
  • SG&A expenses at Rs. 11.0 billion [YoY decline: 6%]
  • EBITDA at Rs. 6.3 billion [17.7% of Revenues]
  • Profit after tax at Rs. 3.1 billion [8.8% of Revenues]

Commenting on the results, Co-chairman and CEO, G V Prasad said, “FY17 has been a challenging year due to lack of new product approvals for the US market. However, our other geographies delivered good performances, with several new product launches. We are also seeing expanded global access to our Biosimilars, as a result of successful registrations in Emerging Markets. We will continue our focus on rationalisation of cost structures and building a sustainable quality culture across the organisation.”

All amounts in millions, except EPS
All US dollar amounts based on convenience translation rate of I USD = Rs. 64.85

 

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement for Q4 FY 17

 
        Q4 FY17   Q4 FY16    
Particulars       ($)   (Rs.)   %   ($)   (Rs.)   %   Growth %
Revenues       548   35,542   100.0   579   37,562   100.0   (5 )
Cost of revenues       268     17,360     48.8     251     16,286     43.4     7  
Gross profit       280     18,182     51.2     328     21,276     56.6     (15 )
Operating Expenses
Selling, general & administrative expenses 169 10,973 30.9 179 11,632 31.0 (6 )
Research and development expenses 71 4,579 12.9 75 4,879 13.0 (6 )
Other operating (income) / expense       (8 )   (505 )   (1.4 )   (5 )   (307 )   (0.8 )   64  
Results from operating activities       48     3,135     8.8     78     5,072     13.5     (38 )
Net finance expense 1 48 0.1 41 2,646 7.0 (98 )
Share of (profit) / loss of equity accounted investees       (2 )   (102 )   (0.3 )   (1 )   (59 )   (0.2 )   72  
Profit before income tax       49     3,189     9.0     38     2,485     6.6     28  
Income tax expense       1     64     0.2     27     1,739     4.6     (96 )
Profit for the period       48     3,125     8.8     11     746     2.0     319  
            -             -          
Diluted EPS       0.29     18.83         0.07     4.36         332  
 

EBITDA Computation

 
Particulars       Q4 FY 17   Q4 FY 16
      $   Rs.   $   Rs.
Profit before income tax 49   3,189   38   2,485
Interest income, net* (1 ) (90 ) (11 ) (713 )
Depreciation# 36 2,338 32 2,062
Amortization       13     866     15     970  
EBITDA       97     6,303     74     4,804  
EBITDA% to Revenues           17.7 %       12.8 %

* Includes income from Investments; # Includes Impairment charge

 

Key Balance Sheet Items

 
Particulars       As on 31st Mar 17       As on 31st Dec 16
      ($)   (Rs.)       ($)   (Rs.)
Cash and cash equivalents and Other current Investments       280     18,136       311     20,145
Trade Receivables       587     38,065       634     41,119
Inventories       440     28,529       463     30,052
Property, plant and equipment       881     57,160       882     57,209
Goodwill and Other Intangible assets       751     48,677       771     49,977
Loans and borrowings (current & non-current)       758     49,185       894     57,999
Trade & other payables       207     13,417       205     13,308
Equity       1,913     1,24,044       1,866     121,040
 

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement for FY 17

 
        FY17   FY16    
Particulars       ($)   (Rs.)   %     ($)   (Rs.)   %     Growth %
Revenues       2,171   1,40,809   100.0   2,386   1,54,708   100.0   (9 )
Cost of revenues       963     62,453     44.4     963     62,427     40.4     0  
Gross profit       1,208     78,356     55.6     1,423     92,281     59.6     (15 )
Operating Expenses
Selling, general & administrative expenses 715 46,372 32.9 705 45,702 29.5 1
Research and development expenses 301 19,551 13.9 275 17,834 11.5 10
Other operating (income) / expense       (16 )   (1,065 )   (0.8 )   (13 )   (874 )   (0.6 )   22  
Results from operating activities
Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 三井化学开发全球首款灵活的高强度柔性无纺布AIRYFA™
  • APR应用制药研究公司参加第9届ChinaBio®合作论坛:依托瑞士创新产品和科学技术深耕中国市场
  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定